Advisory - One lot of the hypoglycemia treatment Glucagon recalled as it may pose serious health risks
OTTAWA, Sept. 25, 2021 /CNW/ -
Summary
Product: Glucagon (DIN 02243297, lot D239382A, expiry May 10, 2022)
Issue: Eli Lilly Canada Inc. is recalling one lot of Glucagon, following a complaint that a vial from this lot was found to be in liquid form instead of powder form. Glucagon normally comes in a powder form with accompanying diluting solution and should be used immediately after mixing.
What to do: Do not use product from this lot. Call 9-1-1 immediately if you or a family member, including children, have taken this product and are experiencing medical issues, such as hypoglycemia (low blood sugar) or seizures. Consult with your doctor or pharmacist if you have any questions or concerns about the product you are taking.
Issue
Eli Lilly Canada Inc. is recalling one lot of Glucagon (D239382A, expiry May 10, 2022), following a complaint that a vial from this lot was found to be in liquid form rather than powder form. Glucagon normally comes in a powder form with accompanying diluting solution, and should be used immediately after mixing. Other vials in the lot may be affected.
Vials from the affected lot may not work as intended in treating patients with hypoglycemia (low blood sugar) resulting in persisting hypoglycemia. It could also cause other serious health consequences, such as unconsciousness and seizures.
Glucagon is a prescription drug administered by injection for the emergency treatment of severe hypoglycemia (unconsciousness due to low blood sugar), which may occur in diabetic patients (children and adults) treated with insulin.
Health Canada is monitoring the effectiveness of the company's recall and the implementation of any necessary corrective and preventative actions.
What consumers should do
Call 9-1-1 immediately if you or your child have taken this product and are experiencing medical issues, such as hypoglycemia or seizures.
Do not use Glucagon from the Lot D239382A.
Contact Eli Lilly Canada Inc. at 1-888-545-5972 if you have questions about the recall.
WomenHeart: The National Coalition for Women with Heart Disease, in collaboration with Bayer, is proud to announce the launch of the Understanding Her Heart: Women and Cardiovascular Disease initiative. This groundbreaking partnership aims to bolster...
ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the publication of results from SLIM LIVER (also known as A5371) in the Annals of Internal Medicine. "The Effect of Open-Label Semaglutide on...
"My husband uses supplemental oxygen, and he needed a way to prevent continual kinks in the line," said an inventor, from Greenville, S.C., "so I invented the No Kink. My design helps provide continuous air flow, and it could also help prevent...
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has experienced a year of achievements across its three Centres of Excellence?Oncology, Genomics, and Transplantation. KFSH&RC's Oncology Centre of Excellence continues to lead the fight...
"I wanted to create a new type of mosquito repellant that can be worn on any area of the body to deter bites and irritation," said an inventor, from Waterbury, Conn., "so I invented the BYE BYE. My design enables you to enjoy a backyard party,...
Serotonin Centers, the nation's fastest-growing anti-aging/longevity franchise, has announced plans to continue the buildout of the brand's West Coast roots, having finalized its latest development deal for a new center in San Diego. A San...